Somatostatin effects on the cyclic AMP system and lipid metabolism in mouse brain.
The effect of somatostatin on cyclic AMP-protein kinase system and lipid metabolism was studied in mouse brain. Subcutaneous injection of the peptide decreased the cyclic AMP and cyclic GMP levels (70% and 60% respectively) as well as protein kinase and triglyceride lipase activities (30%). Cyclic AMP binding protein activity was not affected. Experiments carried out with [14C]acetate as precursor of lipids seem to indicate that somatostatin blocks the fatty acid turnover. On the other hand, the general decrease of 32P incorporation into all phospholipids by somatostatin suggests that the peptide interferes with the precursor uptake into phospholipids. The findings reported here indicate that somatostatin has a role on brain metabolism and further add more data in support for its neuromodulating action.
Catalan
R E
RE
Martinez
A M
AM
Miguel
B G
BG
Robles
A
A
Aragones
M D
MD
D000085:Acetates / Q000378:metabolism; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects*; D002352:Carrier Proteins / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism*; D002373:Cyclic AMP Receptor Protein; D006152:Cyclic GMP / Q000378:metabolism; D007279:Injections, Subcutaneous; D050356:Lipid Metabolism; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010743:Phospholipids / Q000378:metabolism; D013004:Somatostatin / Q000494:pharmacology*
D000085:Acetates; D002352:Carrier Proteins; D002373:Cyclic AMP Receptor Protein; D010743:Phospholipids; D013004:Somatostatin; D000242:Cyclic AMP; D006152:Cyclic GMP